This trial tested how two drugs, Ruzasvir & Bemnifosbuvir, interact when taken together to treat Hepatitis C.
2 Primary · 0 Secondary · Reporting Duration: Days 6, 12, 18
2 Treatment Groups
BEM vs BEM + Ruzasvir n=16
1 of 2
Ruzasvir vs Ruzasvir + BEM n=16
1 of 2
32 Total Participants · 2 Treatment Groups
Primary Treatment: BEM vs BEM + Ruzasvir n=16 · No Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Age 18 - 55 · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is this research accommodating individuals over 45 years of age?
"Individuals aged between 18 and 55 can join this clinical trial." - Anonymous Online Contributor
What are the relative safety implications of BEM alone versus a combination treatment with BEM and Ruzasvir among 16 patients?
"The safety of BEM combined with Ruzasvir, based on the small sample size of 16 patients, has been deemed a 1 due to its Phase 1 clinical trial status. This implies that there is only limited data available supporting both safety and efficacy." - Anonymous Online Contributor
Is this trial currently open for enrollment?
"Affirmative. According to clinicaltrials.gov, this medical trial is presently searching for volunteers and was first posted on January 30th 2023 with the latest update occurring on February 9th of that same year. 32 individuals are required from 1 trial site in total." - Anonymous Online Contributor
How many participants are actively involved in this clinical investigation?
"Affirmative. Clinicaltrials.gov records point to this medical study still recruiting patients, which was initially posted on January 30th 2023 and last updated February 9th of the same year. There are 32 positions available at a single site for prospective participants." - Anonymous Online Contributor
Are there any particular demographics that would make someone a favorable candidate for this clinical trial?
"This clinical trial requires 32 volunteers aged 18-55 with a healthy body weight of 50 kilograms and BMI between 18-29 kg/m2. In addition, participants must agree to use two forms of contraception from Screening through 90 days after taking the last dose of medication. Furthermore, all candidates must be willing to comply with the study's requirements and provide written informed consent." - Anonymous Online Contributor